US20250346681A1 - T cell binding proteins - Google Patents

T cell binding proteins

Info

Publication number
US20250346681A1
US20250346681A1 US18/854,215 US202318854215A US2025346681A1 US 20250346681 A1 US20250346681 A1 US 20250346681A1 US 202318854215 A US202318854215 A US 202318854215A US 2025346681 A1 US2025346681 A1 US 2025346681A1
Authority
US
United States
Prior art keywords
seq
cell
binding protein
tumor
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/854,215
Other languages
English (en)
Inventor
Mark Cobbold
Corinne Cayatte
Jonathan Christopher Joel SEAMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US18/854,215 priority Critical patent/US20250346681A1/en
Publication of US20250346681A1 publication Critical patent/US20250346681A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site.
  • the disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins.
  • the disclosure further relates to methods of treating a disorder or condition using such binding proteins.
  • TCEs CD3-based bispecific T cell engagers
  • TCEs simultaneously bind a tumor associated antigen (TAA) and cluster of differentiation 3 (CD3) on a T cell to form a T cell receptor (TCR)-independent artificial immune synapse, circumventing human leukocyte antigen (HLA) restriction, and inducing T cell activation and cytolysis of the tumor cell.
  • TAA tumor associated antigen
  • CD3 cluster of differentiation 3
  • HLA human leukocyte antigen
  • the first generation of TCEs were simple bispecific T cell engagers (BiTEs), composed of two tandem single-chain variable fragments (scFvs) including a strong CD3-binding arm and a TAA binding domain.
  • BiTEs simple bispecific T cell engagers
  • scFvs tandem single-chain variable fragments
  • CD3 using the Orthoclone OKT3 antibody
  • CD19 cluster of differentiation 19
  • BiTE formats exhibit very short half-life and have poor manufacturability (Ellerman, “Bispecific T cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety,” Methods 154: 102-17 (2019)).
  • the second generation of TCEs include a fragment crystallizable (Fc) domain which can be modified to confer half-life extension and mutations to eliminate Fc receptor (FcR) binding, and present improved manufacturability (Vafa et al., “Perspective: Designing T cell Engagers With Better Therapeutic Windows,” Front Oncol. 10: 446 (2020)). Nevertheless, those molecules still include high affinity-CD3 binding domains, linking to induction of neurotoxicity and CRS in the clinic.
  • Fc fragment crystallizable domain
  • both CD3-based BiTEs and novel immunoglobulin G (IgG)-format TCEs bind and activate both cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells, potentially engaging unfavorable T cells such as regulatory T cells (Treg), which have been shown to potentially decrease the cytolytic activity of CD8 T cells (Duell et al., “Frequency of regulatory T cells determines the outcome of the T cell-engaging antibody blinatumomab in patients with B-precursor ALL,” Leukemia 31: 2181-90 (2017)).
  • CD4 cluster of differentiation 4
  • CD8 T cells regulatory T cells
  • T cell engager molecules offer promise, the therapeutic approach has faced challenges to date. There is a need in the art for improved T-cell binding proteins with increased activity and reduced off-target effects.
  • the disclosure provides a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the first and second polypeptide chains have a structure represented by the formula: V L -C L and a third polypeptide chain has a structure represented by the formula: V H1 -C H1 -V H2 -Fc and a fourth polypeptide chain has a structure represented by the formula: V H1 -C H1 -V H3 -Fc wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the formula: V L -C L and two polypeptide chains have a structure represented by the formula: II 1 -V H1 -C H1 -V H2 -Fc-II 2 ; wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a heavy chain variable domain that specifically binds a T cell receptor; Fc is C H2 and C H3 immunoglobul
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise (a) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; (b) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 4; (c) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 9, and SEQ ID NO: 10; (d) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 11, and SEQ ID NO: 12; (e) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 13, and SEQ ID NO: 14; (f) the amino acid of sequences of SEQ ID NO: 1 and SEQ ID NO: 19; (g) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 22, and
  • a binding protein comprising three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise the amino acid of sequences of (p) SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45; or (q) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 12.
  • FIG. 1 illustrates a representative binding protein format of the present disclosure, including two binding sites to a tumor associated antigen (TAA), one binding site to T cell receptor (TCR) on T cells, and one binding site to a T cell costimulatory molecule.
  • TAA tumor associated antigen
  • TCR T cell receptor
  • T cell costimulatory molecule Upon cleavage by tumor specific protease at the site indicated, the Fc domain is released, and T cells are activated through TCR binding and activation of a costimulatory receptor.
  • FIGS. 2 A- 2 B illustrate the structure of binding proteins that were evaluated in different in vitro assays.
  • FIG. 2 A illustrates the MCAZ 6.9 binding protein including protease cleavage sites.
  • FIGS. 3 A- 3 C show line graphs depicting assessment of MCAZ 6.9 and MCAZ 6.10 binding proteins in vitro cytolysis on CD20+ B cell lines. The EC50 of both MCAZ 6.9 and MCAZ 6.10 is shown for each cell line.
  • FIG. 3 A illustrates cytolysis assessment using Daudi cells and purified pan T cells.
  • FIG. 3 B illustrates cytolysis assessment using Ramos cells and purified pan T cells.
  • FIG. 3 C illustrates cytolysis assessment using Raji cells and PBMCs.
  • FIGS. 5 A- 5 B show line graphs depicting percentage of surface CD25+ cells using Ramos cells. CD25+ assessment is used as a means of analyzing CD4 and CD8 T cell activation profiles.
  • FIG. 5 A shows results with the MCAZ 6.9 binding protein.
  • FIG. 5 B shows results with the MCAZ 6.10 binding protein.
  • FIGS. 7 A- 7 C show in vitro cytolysis and T cell activation profiles induced by CD20 T cell MCAZ 88 binding protein.
  • FIG. 7 A shows a representative structure of the MCAZ 88 binding protein.
  • FIG. 7 B shows that MCAZ 88 induced cytolysis assessed on Raji cell line (CD20+, 85371 antigen per cell).
  • FIG. 7 C shows CD4 and CD8 T cell activation profiles assessed by measuring the % of surface CD25+ cells.
  • FIG. 8 A is schematic representation of MCAZ 7.5 and MCAZ 89.
  • FIGS. 8 B- 8 C show bar graphs illustrating non-specific CD4 and CD8 T cell activation in solution as assessed by flow cytometry detecting CD25+ status. Binding proteins as shown from top to bottom in the legend are depicted from left to right along the x axis.
  • FIG. 8 B shows non-specific CD8 activation.
  • FIG. 8 C shows non-specific CD4 activation.
  • FIGS. 9 A- 9 B show bar graphs illustrating non-specific CD8 and CD4 T cell activation in plate-adsorbed antibodies as assessed by flow cytometry detecting CD25+ surface expression.
  • FIG. 9 A shows non-specific CD8 activation. Binding proteins as shown from top to bottom in the legend are depicted from left to right along the x axis.
  • FIG. 9 B shows non-specific CD4 activation.
  • FIGS. 10 A- 10 E show in vitro cytolysis and T cell activation profiles induced by uncleavable binding proteins.
  • FIG. 10 A shows the structure of the MCAZ 7.1 binding protein.
  • FIG. 10 B shows the structure of the MCAZ 10.3 binding protein.
  • FIG. 10 C shows that cytolysis was assessed on CD20+ B cell lines Toledo, Oci-LY18, and SU-DHL5 (respectively expressing 12420, 20244, and 27152 CD20 antigen per cell).
  • FIG. 10 D shows MCAZ 7.1 cytolysis EC50 values for each cell line.
  • FIG. 10 E shows CD4 and CD8 T cell activation assessed as % CD25 expressing cells.
  • Non-specific CD8 and CD4 T cell activation levels were assessed by flow cytometry as % CD69+/CD25+ surface expression.
  • FIG. 11 E shows the structure of the MCAZ 10.1 binding protein with a more rigid CD8 arm by removal of TGGS (SEQ ID NO: 46) linker and HA tag, in addition to the removal of cleavable linkers.
  • FIG. 11 F shows that cytolysis was assessed on OCI-Ly18 B cell line. B cell lines were CTV stained and incubated PBMCs at an E:T ratio of 5:1 for 3 days. % cytolysis was measured by flow cytometry.
  • FIGS. 11 G and 11 H show CD8 and CD4 T cell activation profile were assessed as % CD25 expressing cells.
  • FIGS. 12 A- 12 E show the evaluation of the impact of CD8 positioning on the binding protein.
  • FIG. 12 A shows the structure of the MCAZ 8.71 binding protein.
  • FIG. 12 B shows the structure of MCAZ 8.81 binding protein.
  • FIG. 12 C shows cytolysis was assessed on CD20+ B Raji cell line (expressing 85000 CD20 antigen per cell).
  • FIG. 12 D shows cytolysis EC50 values for each cell line.
  • FIG. 12 E shows CD4 and CD8 T cell activation profile assessed as % CD25 expressing cells.
  • FIGS. 13 A- 13 E show evaluation of TCR VHH and CD8 VHH bispecific binding proteins.
  • FIG. 13 A shows the structure of the MCAZ 8.69 binding protein.
  • FIG. 13 B shows the structure of the MCAZ 8.70 binding protein.
  • FIG. 13 C shows cytolysis assessed on CD20+ B Raji cell line (expressing 85000 CD20 antigen per cell).
  • FIG. 13 D shows cytolysis EC50 values for each cell line.
  • FIG. 13 E shows CD4 and CD8 T cell activation profiles assessed as % CD25 expressing cells.
  • FIGS. 14 A- 14 B show non-specific T cell activation assessment for various binding proteins. Different concentrations of binding proteins were plate-bound and 1.5e5 purified T cells were added, in the absence of tumor cells and associated proteases. After 48 h incubation, unspecific ( FIG. 14 A ) CD8 and ( FIG. 14 B ) CD4 T cell activation levels were assessed by flow cytometry as % CD69+/CD25+ surface expression.
  • FIG. 15 A is a schematic of MCAZ 8.71 binding proteins with different Fc regions.
  • FIG. 15 B shows the cytolytic activity of the binding proteins at 72 h on OCI-Ly18 B cell line, with PBMCs at E:T ratio of 5:1.
  • FIGS. 15 C and 15 D show CD8 and CD4 T cell activation profiles assessed by measuring the % of surface CD25+ T cells.
  • FIGS. 16 A- 16 C show the cytolytic activity of a MCAZ 7.1 variant (TENG0093) with modified linkers. Specifically, the variant included similar linkers on the CD8 and TCR VHH arms as indicated on FIG. 16 A . The variant had a different profile than a broad CD3 ⁇ CD20 bivalent engager.
  • FIG. 16 A shows the structure of the modified MCAZ 7.1 with different linkers and the broad CD3 ⁇ CD20 bivalent engager used as the comparator.
  • FIG. 16 B shows the cytolytic activity of the MCAZ 7.1 variant and CD3 ⁇ CD20 bivalent engager on OCI-Ly18 B cell line.
  • FIG. 16 C shows the CD4 and CD8 T cell activation profiles assessed at 72 h as surface expression of CD25.
  • FIGS. 17 A- 17 F show that MCAZ 7.1 exhibited strong binding to CD8 T cells and induced preferential association of CD20+ tumor cells with CD8 T cells compared to the broad CD3 ⁇ CD20 bivalent engager.
  • FIG. 17 A shows MCAZ 7.1 binding profile on CD20+ tumor B cell line (OCI-Ly-18), on ( FIG. 17 B ) purified CD4 and ( FIG. 17 C ) CD8 T cells from PBMCs from healthy donors.
  • FIG. 17 D shows magnification of the CD3 ⁇ CD20 bivalent engager binding to CD8 T cells. The % of CD8-B cell conjugates and CD4-T cell conjugate was assessed by flow cytometry after staining of CD4 and CD8 T cells after ( FIG. 17 E ) incubation with MCAZ 7.1 and ( FIG. 17 F ) the CD3 ⁇ CD20 bivalent engager.
  • FIGS. 18 A- 18 F show that MCAZ 7.1 selective engagement of CD8 T cells during cytolysis was associated with significantly lower cytokine release than broad CD3+ T cell engagement by the CD3 ⁇ CD20 bivalent engager.
  • the MCAZ 7.1 binding protein and the CD3 ⁇ CD20 bivalent engager were incubated with OCI-Ly18 B cell line and PBMCs at an E:T ratio of 5:1 for 72 h.
  • Supernatants were harvested and analyzed by multiplex assay to measure the concentrations of released pro-inflammatory cytokines: ( FIG. 18 A ) TL-6, ( FIG. 18 B ) TNF- ⁇ , ( FIG. 18 C ) IL-10, ( FIG. 18 D ) IFN-g, ( FIG. 18 E ) IL-2, and ( FIG. 18 F ) IL-17A.
  • FIGS. 19 A- 19 B show that MCAZ 7.1 did not induce significant level of T cell activation and cytokine release compared to the CD3 ⁇ CD20 bivalent engager.
  • Various concentrations of the MCAZ 7.1 binding protein and the CD3 ⁇ CD20 bivalent engager were plate-bound and 1.5e5 PBMCs from healthy donor was added and incubated for 48 h.
  • FIG. 19 A shows CD4 and CD8 non-specific T cell activation profiles assessed for CD25/CD69+ surface expression levels by flow cytometry.
  • FIG. 19 B shows multiplex assay measuring the concentrations of released pro-inflammatory cytokines for harvested supernatants.
  • FIGS. 20 A- 20 B show that the MCAZ 7.1 variant (TENG0093) binding protein and the CD3 ⁇ CD20 bivalent engager induced strong cytolytic activity in a 3D-spheroid model.
  • GFP-expressing CD20+ B cell line TMD8, 100 000 CD20/cell
  • purified panT cells were added at a 15:1 E:T ratio and co-incubated with no engager, the MCAZ 7.1 variant binding protein, or the CD3 ⁇ CD20 bivalent engager for 96 h.
  • FIG. 20 A shows a representative image of spheroids in the absence of binding protein, with the MCAZ 7.1 variant binding protein or with the CD3 ⁇ CD20 bivalent engager.
  • FIG. 20 B shows the average % of GFP signal intensity relative to no engager control at various concentrations of T cell engagers after 96 hours incubation.
  • FIG. 21 shows PK assessment after a single dose of the MCAZ 7.1 binding protein.
  • NSG mice humanized with panT cells were injected with 0.5 mg/kg of binding protein as indicated and systemic concentrations of binding proteins were measured after 1 h, 6 h, 24 h, 48 h, 72 h, and 168 h.
  • FIG. 22 shows in vivo efficacy of the MCAZ 7.1 binding protein in B cell lymphoma in a humanized NSG mouse model.
  • NSG mice were engrafted with panT cells two days prior to the study start.
  • 5e6 OCI-Ly18 CD20+ tumor cell lines were implanted s.c. at day 0 and animals were dosed i.p. with 1 mg/kg of MCAZ 7.1 binding protein or CD3 ⁇ CD20 bivalent engager at day 2, followed by weekly dosing at the same concentration as indicated by the grey arrows under the X axis.
  • FIGS. 23 A- 23 F show in vivo cytokine release assessment of the MCAZ 7.1 binding protein compared to the CD3 ⁇ CD20 bivalent engager in a CRS mouse model. Mean+/ ⁇ SD are plotted for ( FIG. 23 A ) TL-6, ( FIG. 23 B ) TNF- ⁇ , ( FIG. 23 C ) IL-10, ( FIG. 23 D ) IFN-g, ( FIG. 23 E ) IL-2, and ( FIG. 23 F ) IL-17A.
  • FIGS. 24 A- 24 H show binding protein in vitro activity for MCAZ 7.1 and the MCAZ 7.1 variant on PBMCs from Non-Hodgkin lymphoma (NHL) donors.
  • B cell killing was assessed on PBMCs from NHL (DLBCL) donors.
  • the MCAZ 7.1 variant binding protein was spiked in the PBMCs at the indicated concentrations and 48 h later, % B cells was assessed by flow cytometry for each patient ( FIGS. 24 A, 24 C, 24 E and 24 G ).
  • the % B cell cytolysis is presented at the different concentrations of binding proteins indicated for 3 different DLBCL donors ( FIGS. 24 B, 24 D, 24 F, 24 H ) CD4 and CD8 T cell activation profiles were assessed as % of CD25+ T cells.
  • FIGS. 25 A- 25 B show a representative molecular format of EGFR TITAN and a broad CD3 engager that was used as a comparator.
  • FIGS. 26 A- 26 B show the binding profiles of EGFR TITAN (MCAZ13.8) and broad CD3 comparator on NCIH196 ( 26 A) and MDA-MB231 ( 26 B).
  • FIGS. 27 A- 27 B show in vitro cytotoxicity and T cell activation profiles for NCIH196-EGFR high.
  • 27 A shows equivalent cytolytic activities of EGFR TITAN and the broad CD3 engager used as a comparator on the NCIH196 tumor cell line.
  • 27 B shows strong biased CD8 T cell activation profile for EGFR TITAN (MCAZ13.8) as highlighted by the % CD25 surface expression on T cells.
  • FIGS. 28 A- 28 E show that EGFR TITAN (MCAZ13.8) selective engagement of CD8 T cells during cytolysis is associated with significantly lower cytokine release than broad CD3+ T cell engagement by CD3 ⁇ EGFR bivalent comparator.
  • FIGS. 29 A- 29 B show in vitro cytotoxicity and T cell activation bias for MDA-MB-231-EGFR high.
  • FIG. 29 A shows equivalent cytolytic activities of EGFR TITAN and broad CD3 engager used as a comparator on MDA-MB-231 tumor cell line.
  • FIG. 29 B shows strong biased CD8 T cell activation profile for EGFR TITAN (MCAZ13.8) as highlighted by the % CD25 surface expression on T cells.
  • FIGS. 30 A- 30 E show that EGFR TITAN (MCAZ13.8) selective engagement of CD8 T cells during cytolysis is associated with significantly lower cytokine release than broad CD3+ T cell engagement by CD3 ⁇ EGFR bivalent comparator.
  • FIGS. 31 A- 31 B show T cell activation.
  • FIG. 31 A shows that EGFR TITAN (MCAZ 13.8) binding protein does not activate T cells when plate-bound at different concentrations. In comparison the broad CD3 engager used as a comparator induces significant T cell activation at the highest concentrations used.
  • FIG. 31 B shows that the absence of T cell activation induced by plate-bound EGFR TITAN (MCAZ 13.8) is associated with absence of cytokine release.
  • FIGS. 32 A- 32 C show TENG0093 potently depletes B cells in fully humanized NSG mice.
  • NSG-SGM3 mice were humanized with human stem cells (CD34+ cells).
  • animals were treated I.P. with 20 mg/kg of Fc block and 16 h later treated I.P. with 1 mg/kg of TENG0093 or CD3 ⁇ CD20 bivalent engager.
  • B cell depletion efficacy was assessed by flow cytometry using anti-CD19 surface staining. Both CD20 T cell engagers induced potent and nearly complete B cell depletion efficacy in blood ( 32 A), spleen ( 32 B), and bone marrow ( 32 C) compared to PBS treated groups (no treatment group).
  • the disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site.
  • the disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins.
  • the disclosure further relates to methods of treating a disorder or condition using such binding proteins.
  • the binding proteins disclosed herein preferentially bind to CD8+ T cells.
  • the binding proteins avoid engagement with tumor promoting T cells such as Treg, Th2 and Th17 cells and avoid engagement with CD4+ T cells which produce the majority of cytokines that cause release syndrome (CRS).
  • CRS cytokines that cause release syndrome
  • the binding proteins disclosed herein reduce CRS.
  • the CD8+ T cells bound by the binding proteins disclosed herein induce a type of programmed cell death termed pyroptosis that is immunogenic.
  • a pyroptotic cell is taken up by antigen presenting cells and may drive further tumor-specific T cell responses.
  • Percentages disclosed herein can vary in amount by ⁇ 10, 20, or 30% from values disclosed and remain within the scope of the contemplated disclosure.
  • ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. For example, “about 5%” means “about 5%” and also “5%.” The term “about” can also refer to +10% of a given value or range of values. Therefore, about 5% also means 4.5%-5.5%, for example.
  • x, y, and/or z can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.”
  • binding protein refers to a non-naturally occurring (or recombinant) molecule which comprises multiple polypeptide chains that form at least one antigen binding site.
  • a “recombinant” molecule is one that has been prepared, expressed, created, or isolated by recombinant DNA technology means.
  • antibody refers to a protein that is capable of recognizing and specifically binding to an antigen.
  • Ordinary or conventional mammalian antibodies comprise a tetramer, which is typically composed of two identical pairs of polypeptide chains, each pair consisting of one “light” chain (typically having a molecular weight of about 25 kDa) and one “heavy” chain (typically having a molecular weight of about 50-70 kDa).
  • each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition.
  • the variable domain may be subjected to further protein engineering to humanize the framework regions if the antibody was derived from a non-human source.
  • the carboxyl-terminal portion of each chain typically defines a constant domain responsible for effector function.
  • a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V H ) and three constant domains (C H1 , C H2 , and C H3 ) and a hinge region between C H1 and C H2 , wherein the V H domain is at the amino-terminus of the polypeptide and the C H3 domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (V L ) and a constant domain (C L ), wherein the V L domain is at the amino-terminus of the polypeptide and the C L domain is at the carboxyl-terminus.
  • variable and constant domains typically are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
  • the variable regions of each light/heavy chain pair typically form an antigen binding site.
  • the variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
  • the CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope.
  • both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • Antigen-binding fragment thereof refers to at least the minimal portion of an antibody which is capable of binding to a specified antigen which the antibody targets, e.g., at least some of the complementarity determining regions (CDRs) of the variable domain of a heavy chain (V H ) and the variable domain of a light chain (V L ) in the context of a typical antibody produced by a B cell.
  • CDRs complementarity determining regions
  • Antibodies or antigen-binding fragments thereof can be or be derived from polyclonal, monoclonal, human, humanized, or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab′ and F(ab′)2, Fd, Fvs, single-chain Fvs (scFvs), single-chain antibodies, disulfide-linked Fvs (sdFvs), fragments comprising either a V L or V H domain alone or in conjunction with a portion of the opposite domain (e.g., a whole V L domain and a partial V H domain with one, two, or three CDRs), and fragments produced by a Fab expression library.
  • ScFv molecules are known in the art and are described, e.g., in U.S. Pat. No. 5,892,019.
  • native Fc refers to a molecule comprising the sequence of a non-antigen binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region.
  • the original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins.
  • Native Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association.
  • the number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2).
  • class e.g., IgG, IgA, and IgE
  • subclass e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2
  • One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG.
  • native Fc is generic to the monomeric, dimeric, and multimeric forms.
  • Fc variant refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the salvage receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed or mutated to produce an Fc variant to alter certain residues that provide structural features or biological activity that are not required for the binding proteins of the disclosure.
  • Fc variant comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).
  • ADCC antibody-dependent cellular cytotoxicity
  • Binding proteins encompassed by this disclosure can be of or be derived from any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.
  • type e.g., IgG, IgE, IgM, IgD, IgA, and IgY
  • class e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2
  • subclass of immunoglobulin molecule e.g., immunoglobulin molecule.
  • antigen or “target antigen,” as used herein, refers to a molecule or a portion of a molecule that is capable of being recognized by and bound by the antigen binding portion of the binding proteins of the disclosure.
  • the target antigen is capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen.
  • a target antigen may have one or more epitopes. With respect to each target antigen recognized by the antigen binding portion of the binding protein, is capable of competing with an intact antibody that recognizes the target antigen.
  • antigen binding site refers to a site created on the surface of a binding protein of the disclosure where an antigen or an epitope on an antigen is bound.
  • linker refers to one or more amino acid residues inserted between domains of the binding protein of the disclosure.
  • a linker may be inserted between domains, at the sequence level. The precise location of a domain transition can be determined by locating peptide stretches that do not form secondary structural elements such as beta-sheets or alpha-helices as demonstrated by experimental data or as can be assumed by techniques of modeling or secondary structure prediction. Linkers may or may not be needed depending on the where the stop and start residues of protein fusions are chosen because often natural linkers are found between immunoglobulin domains.
  • nucleotide includes a singular nucleic acid as well as multiple nucleic acids, and refers to an isolated nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA (pDNA).
  • mRNA messenger RNA
  • pDNA plasmid DNA
  • nucleic acid includes any nucleic acid type, such as DNA or RNA.
  • vector can refer to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
  • a vector can include nucleic acid sequences that permits it to replicate in a host cell, such as an origin of replication.
  • a vector can also include one or more selectable marker gene and other genetic elements known in the art. Specific types of vector envisioned here can be associated with or incorporated into viruses to facilitate cell transformation.
  • treating refers to reducing disease pathology, reducing or eliminating disease symptoms, promoting increased survival rates, and/or reducing discomfort.
  • treating can refer to the ability of a therapy to reduce disease symptoms, signs, or causes when administered to a subject. Treating also refers to mitigating or decreasing at least one clinical symptom and/or inhibition or delay in the progression of the condition and/or prevention or delay of the onset of a disease or illness.
  • the terms “subject,” “individual,” or “patient,” refer to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired.
  • Mammalian subjects include, for example, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, bears, and so on.
  • an “effective amount” or a “therapeutically effective amount” of an administered therapeutic substance, such as a binding protein is an amount sufficient to carry out a specifically stated or intended purpose, such as treating or treatment of cancer.
  • An “effective amount” can be determined empirically in a routine manner in relation to the stated purpose.
  • the binding proteins disclosed herein may be formulated with a pharmaceutically acceptable carrier, excipient, or stabilizer, as pharmaceutical compositions.
  • a pharmaceutically acceptable carrier means one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredients.
  • Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
  • Such pharmaceutically acceptable preparations may also contain compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human.
  • contemplated carriers, excipients, and/or additives which may be utilized in the formulations described herein include, for example, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, lipids, protein excipients such as serum albumin, gelatin, casein, salt-forming counterions such as sodium, and the like.
  • These and additional known pharmaceutical carriers, excipients, and/or additives suitable for use in the formulations described herein are known in the art, for example, as listed in “Remington: The Science & Practice of Pharmacy,” 21st ed., Lippincott Williams & Wilkins, (2005), and in the “Physician's Desk Reference,” 60th ed., Medical Economics, Montvale, N.J. (2005).
  • Pharmaceutically acceptable carriers can be selected that are suitable for the mode of administration, solubility, and/or stability desired or required.
  • a binding protein comprising two tumor-associated antigen (TAA) binding sites.
  • the tumor associated antigen (TAA) is cluster of differentiation 20 (CD20).
  • CD20 is a transmembrane protein involved in Ca ++ channeling, B-cell activation, and proliferation.
  • CD20 is a membrane-embedded surface molecule which plays a role in the development and differentiation of B-cells into plasma cells.
  • the binding protein comprises a fragment of rituximab (see, e.g., U.S. Pat. No. 5,736,137).
  • a binding protein comprising one T cell costimulatory molecule binding site.
  • a co-stimulatory molecule comprises a co-stimulatory domain capable of potentiating or modulating the response of immune effector cells.
  • Co-stimulatory domains can include sequences, for example, from one or more of CD3zeta (or CD3z), CD28, CD137 (4-1BB), OX-40, ICOS, CD27, GITR, CD2, IL-2R ⁇ and MyD88/CD40.
  • the T cell costimulatory molecule is CD8.
  • the T cell costimulatory molecule is CD137 (4-1BB).
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the first and second polypeptide chains have a structure represented by the formula: V L -C L ; and a third polypeptide chain has a structure represented by the formula: V H1 -C H1 -V H2 -Fc; and a fourth polypeptide chain has a structure represented by the formula: V H1 -C H1 -V H3 -Fc; wherein V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the formula: V L -C L and two polypeptide chains have a structure represented by the formula: II 1 -V H1 -C H1 -V H2 -Fc-II 2 ; wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a heavy chain variable domain that specifically binds a T cell receptor; Fc is an immunoglobulin hinge region and CH
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the formula: II 1 -V L -C L II 2 ; and two polypeptide chains have a structure represented by the formula: V H1 -C H1 -V H2 -Fc; wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a heavy chain variable domain that specifically binds a T cell receptor; Fc is an immunoglobulin hinge region and C H
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein two polypeptide chains have a structure represented by the formula: V L -C L and one polypeptide chain has a structure represented by the formula: V H1 -C H1 -Fc; and one polypeptide chain has a structure represented by the formula: V H2 -V H3 -Fc; wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH 1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a heavy chain variable domain that specifically binds a T cell
  • a binding protein comprising three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the first polypeptide chain has a structure represented by the formula: V L -C L ; and a second polypeptide chain has a structure represented by the formula: V H1 -C H1 -V H2 -Fc; and a third polypeptide chain has a structure represented by the formula: V H1 -V H3 -Fc; wherein: V L is an immunoglobulin light chain variable domain that specifically binds a tumor-associated antigen; V H1 is an immunoglobulin heavy chain variable domain that specifically binds a tumor-associated antigen; C L is an immunoglobulin light chain constant domain that specifically binds a tumor-associated antigen; C H1 is an immunoglobulin CH1 heavy chain constant domain that specifically binds a tumor-associated antigen; V H2 is a heavy
  • the heavy chain variable domain that specifically binds a T cell receptor binding site is an immunoglobulin heavy chain variable domain. In some aspects, the heavy chain variable domain that specifically binds a T cell receptor binding site is a single domain sequence. In particular aspects, the heavy chain variable domain that specifically binds a T cell receptor binding site is a nanobody. In particular aspects, the heavy chain variable domain that specifically binds a T cell receptor binding site is a camelid. In particular aspects, the heavy chain variable domain that specifically binds a T cell receptor binding site is a single-domain variable new antigen receptor.
  • the binding protein comprises a linker.
  • the identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to be achieved. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with one or more other amino acid residues, which may be the same as or different as the first amino acid residue, to construct larger peptide linkers as necessary depending on the desired properties.
  • the linker comprises the amino acid sequence TGGS (SEQ ID NO: 46). In some aspects, the linker comprises the amino acid sequence GGGGS (SEQ ID NO: 47). In some aspects, the linker comprises the amino acid sequence AAAYPYDVPDYGSGEGTSTGSGGSGGSGGA (SEQ ID NO: 48). In some aspects, the linker further comprises a hemagglutinin tag.
  • the binding protein comprises H 1 , an immunoglobulin hinge region positioned between C H1 and V H2 on the third polypeptide chain and H 2 , an immunoglobulin hinge region positioned between V H2 and the Fc on the third polypeptide chain, wherein H 1 and H 2 are each independently an immunoglobulin hinge region or are absent.
  • the binding protein comprise H 3 , an immunoglobulin hinge region positioned between C H1 and V H3 on the fourth polypeptide chain and H 4 , an immunoglobulin hinge region positioned between V H3 and the Fc on the fourth polypeptide chain, wherein H 3 and H 4 are each independently an immunoglobulin hinge region or are absent.
  • H 1 , H 2 , H 3 , and H 4 are each independently an immunoglobulin hinge region or are absent.
  • the binding protein comprises a first and a second polypeptide chain having a structure represented by the formula:
  • the binding protein comprises a first polypeptide chain having a structure represented by the formula:
  • the binding protein comprises two polypeptide chains having a structure represented by the formula:
  • the binding protein comprises a first polypeptide chain having a structure represented by the formula:
  • the binding protein comprises four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise
  • the binding protein comprises three or four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise
  • the binding protein comprises three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise the amino acid of sequences of SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45 or (q) the amino acid of sequences of SEQ ID NO: 1, SEQ ID NO: 11 and SEQ ID NO: 12.
  • the binding protein comprises three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, comprises the amino acid of sequences of SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45.
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acid sequences having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 1-56.
  • a binding protein comprising four polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acid sequences having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 1-42.
  • a binding protein comprising three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acid sequences having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 1-56.
  • a binding protein comprising three polypeptide chains that form two tumor-associated antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site, wherein the polypeptide chains comprise amino acid sequences having at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 1-42.
  • binding proteins of the disclosure may be prepared using domains or sequences obtained or derived from any human or non-human antibody, including, for example, human, murine, or humanized antibodies.
  • Some aspects of the present disclosure relate to an isolated nucleic acid sequence encoding a binding protein as described herein.
  • the isolated nucleic acid sequence may be included in a vector.
  • the methods disclosed herein relate to treating a subject for cancer by administering an effective amount of a binding protein.
  • the disclosure also provides a therapeutically effective amount of a binding protein for use in treating cancer in a subject.
  • a method for treating a subject for an inflammatory disease by administering an effective amount of a binding protein.
  • a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier, for use as a medicament.
  • a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier, for use in the treatment of cancer.
  • a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disease.
  • a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier, in the manufacture of a medicament for use in the treatment of an inflammatory disease.
  • a binding protein or a pharmaceutical composition comprising the binding protein and a pharmaceutically acceptable carrier, in the manufacture of a medicament for use in the treatment of cancer.
  • the cancer includes B-cell malignancies, including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
  • B-cell malignancies including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
  • the methods disclosed herein relate to treating a subject for an inflammatory disease where B cells are involved by administering an effective amount of a binding protein.
  • the disclosure also provides a therapeutically effective amount of a binding protein for use in treating an inflammatory disease where B cells are involved in a subject.
  • the binding proteins can preferentially activate a subset of T cells in the subject.
  • the subset of T cells can be CD8+ T cells.
  • the CD8+ T cells can be preferentially activated as compared to CD4 T cells.
  • the preferential activation of CD8+ T cells reduces engagement with tumor promoting T cells and CD4+ T cells which produce the majority of cytokines that cause release syndrome (CRS). Additionally, the preferential engagement of the CD8+ T cells induce pyroptosis.
  • the activation of T cells through methods of the present disclosure can be determined by measuring the percentage of surface interleukin-2 receptor alpha chain-positive (CD25+) T cells.
  • the percentage of surface CD25+ T cells that are CD8 T cells can be higher than the percentage of surface CD25+ T cells that are CD4 T cells.
  • activation of T cells can be determined by the percentage of CD69+/CD25+ T cells.
  • activation of T cells can be determined by measuring levels of cytokines released by activated T cells.
  • the method of treatment of the present disclosure can result in reduced engagement of regulatory T cells (Tregs), increased cytolytic activity, and/or reduced incidence of cytokine release syndrome (CRS) relative to that resulting from bispecific T-cell engager (BiTEs) previously known in the art.
  • the disclosure also provides a therapeutically effective amount of a binding protein for use in reducing engagement of regulatory T cells (Tregs), increasing cytolytic activity, and/or reducing incidence of cytokine release syndrome (CRS) relative to that resulting from bispecific T-cell engager (BiTEs) previously known in the art.
  • the inflammatory disease or inflammatory disease where B cells are involved is selected from rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, pemphigus, lupus profundus , sceleroderma, discoid lupus erythematosus, systemic lupus erythematosus, Sjögren's syndrome, atopic dermatitis and allergic contact dermatitis.
  • FIG. 1 shows a representative structure for these binding proteins.
  • binding proteins MCAZ 6.9 and MCAZ 6.10 respectively were generated to include two CD20 binding sites, a CD8 co-stimulatory binding arm ( FIG. 2 A ) and CD137 binding arm ( FIG. 2 B ), a TCR binding domain and two protease cleavage sites.
  • MCAZ 7.1 was generated to include two CD20 binding sites, a CD8 co-stimulatory binding arm, and a TCR binding domain, but did not include the two protease cleavage sites ( FIG. 10 A ).
  • MCAZ 6.9 and MCAZ 6.10 binding proteins were assessed for in vitro cytolysis on CD20+ B cell lines Daudi, Ramos and Raji.
  • B cells and purified pan T cells were incubated with the B cell lines at an E:T ratio of 5:1 for 4 days and % cytolysis was measured by flow cytometry.
  • Cytolysis for MCAZ 7.1 was assessed on CD20+ B cell lines Toledo, Oci-LY18, and SU-DHL5 (respectively expressing 12420, 20244, and 27152 CD20 antigen per cell).
  • B cell lines were CTV stained and incubated PBMCs at an E:T ratio of 5:1 for 4 days.
  • % cytolysis was measured by flow cytometry.
  • FIGS. 3 A- 3 C , FIGS. 10 C & 10 D Cytolysis was associated with potent T cell activation that was biased to CD8 T cells for MCAZ 6.9 and MCAZ 7.1 ( FIGS. 4 A, 5 A, 6 and FIG. 10 E ) and had CD4 biased profile or equivalent CD4/CD8 profiles for MCAZ 6.10 ( FIGS. 4 B, 5 B, and 6 ).
  • MCAZ 88, MCAZ 7.5, MCAZ 89 were each generated with a unique placement of the TCR binding domain or absence of the TCR binding domain.
  • MCAZ 7.5 had the TCR binding domain placed in the hinge portion of the binding protein ( FIG. 8 A ), while the MCAZ 89 binding protein did not include any TCR binding domains ( FIG. 8 A ).
  • MCAZ 88 induced cytolysis was assessed on Raji cell line (CD20+, 85371 antigen per cell). B cells and PBMCs were incubated with the B cell line at an E:T ratio of 5:1 for 4 days and % cytolysis was measured by flow cytometry. CD4 and CD8 T cell activation profiles were also assessed for MCAZ88, MCAZ7.5, and MCAZ89 binding proteins by measuring the % of surface CD25+ cells and % CD69+/CD25+ surface expression. The results demonstrated that the presence of the two TCR-binding domains in the absence of the T-cell co-stimulatory domain were sufficient to induce cytolysis ( FIG. 7 B ).
  • the binding proteins MCAZ 8.71 and MCAZ 8.81 were each generated with two T cell co-stimulatory molecule in a unique placement on the binding protein to evaluate the impact of CD8 positioning on the binding protein function ( FIGS. 12 A- 12 B ). Cytolysis was assessed on CD20+ B Raji cell line (expressing 85000 CD20 antigen per cell). B cell lines were CTV stained and incubated with PBMCs at an E:T ratio of 5:1 for 4 days. % cytolysis was measured by flow cytometry. CD4 and CD8 T cell activation profile were assessed as % CD25 expressing cells.
  • both MCAZ 8.71 and MCAZ 8.81 showed similar cytolysis ( FIGS. 12 C- 12 D ). Cytolysis was associated with potent T-cell activation that was biased to CD8 T cells for MCAZ 8.71 and MCAZ 8.81 ( FIG. 12 E ). These results demonstrate that the position of the co-stimulatory molecule was flexible within the binding protein, however extra molecules did not increase potency of the binding protein.
  • MCAZ 10.3 was generated to include both the CD8 domain and the TCR binding domain on the same polypeptide ( FIG. 10 C ).
  • the T-cell co-stimulatory domain and the T-cell binding domain were also tested on separate binding proteins.
  • MCAZ 8.69 was generated as a binding protein that only included the T-cell co-stimulatory molecule
  • MCAZ 8.70 was generated as a binding protein that only included the TCR binding domain ( FIG. 13 A ). Cytolysis was assessed on CD20+ B Raji cell line, Toledo, Oci-LY18, and SU-DHL5 cell line.
  • B cell lines were CTV stained and incubated with PBMCs at an E:T ratio of 5:1 for 4 days.
  • % cytolysis was measured by flow cytometry.
  • CD4 and CD8 T cell activation profiles were assessed as % CD25 expressing cells. The results demonstrated that the ideal position of the CD8 domain and the TCR binding domain was on separate arms, but present in the same binding protein for cytolysis and T cell activation ( FIGS. 10 C- 10 E and FIG. 13 ).
  • Modified linker lengths were tested to determine the optimal linker for stability and function of the binding protein.
  • MCAZ 7.7 was generated with a modified longer linker (GGGGSGGGGS) positioned between the CD20 binding domain and the TCR-binding domain ( FIG. 11 A ) as compared to MCAZ 7.1 that had a linker (T) positioned between the CD20 binding domain and the TCR-binding domain.
  • MCAZ 10.1 was generated with a more rigid CD8 arm as compared to MCAZ 7.1.
  • MCAZ 10.1 was generated with the linker positioned between the CD20 binding domain and the TCR-binding domain deleted as compared to MCAZ 7.1 that had a linker (T) and a shortened linker (G) positioned between the TCR-binding domain and the Fc as compared to MCAZ 7.1 that had a linker (GEGTSTGSGGSGGSGGA (SEQ ID NO: 49)).
  • T linker
  • G shortened linker
  • MCAZ 7.7 cytolysis was assessed on CD20+ Raji B cell line (expressing 85000 CD20 antigen per cell). B cell lines were CTV stained and incubated PBMCs at an E:T ratio of 5:1 for 4 days. % cytolysis was measured by flow cytometry.
  • cytolysis was assessed on OCI-Ly18 B cell line. B cell lines were CTV stained and incubated PBMCs at an E:T ratio of 5:1 for 3 days. % cytolysis was measured by flow cytometry. T cell activation profile were assessed as % CD25 expressing cells. For MCAZ 7.7, unspecific and specific T cell activation was assessed by having binding proteins plate-bound and 1.5e5 purified T cells were added, in the absence of tumor cells and associated proteases. After 48 h incubation, non-specific CD8 and CD4 T cell activation levels were assessed by flow cytometry as % CD69+/CD25+ surface expression.
  • the modified longer linker in MCZA 7.7 increased levels of cytolysis as compared to MCZA 7.1, however the longer linker in MCZA 7.7 resulted in non-specific T cell activation.
  • FIG. 15 A Various binding proteins as illustrated in FIG. 15 A were generated to test different uncleavable Fc Regions including IgG1 (MCAZ 11.1), IgG2 (MCAZ 11.2), IgG3 (MCAZ 11.3), IgG4 (MCAZ 11.5), mutated IgG1 (MCAZ 11.5), IgD (MCAZ 11.6) and IgA1 (MCAZ 11.7).
  • the cytolytic activity of the binding proteins was tested at 72 h on OCI-Ly18 B cell line, with PBMCs at E:T ratio of 5:1.
  • CD8 and CD4 T cell activation profiles were assessed by measuring the % of surface CD25+ T cells.
  • the binding proteins with the IgG Fc regions were most effective at cytolysis and inducing T cell activation ( FIGS. 15 B- 15 D ).
  • novel binding proteins disclosed herein were compared to a broad CD20 bivalent engager established as effective in clinical treatment.
  • the activity of a variant of MCAZ 7.1 and a broad CD3 ⁇ CD20 bivalent engager was compared ( FIG. 16 A ).
  • the variant included a linker between the CD20 binding domain and the CD8 domain and a linker between the CD20 binding domain and the TCR domain (TGGS (SEQ ID NO: 46)), as well as a linker between the CD8 domain and the Fc region and the TCR domain and the Fc domain (GGGGS (SEQ ID NO: 47)).
  • the binding protein and bivalent engager were incubated with target CD20+ cells for 72 h at an E:T ratio of 5:1 with PBMCs from a healthy donor.
  • the MCAZ7.1 variant induced similar E max cytolysis ( ⁇ pM EC50) but with a distinct significant CD8-biased activation profile ( FIG. 16 B ).
  • the binding to CD8 T cells of the variant of MCAZ 7.1 and the CD3 ⁇ CD20 bivalent engager was compared.
  • the MCAZ7.1 variant binding profile was assessed on CD20+ tumor B cell line (OCI-Ly-18), on purified CD4 and CD8 T cells from PBMCs from healthy donors.
  • OCI-Ly18 tumor cells were CTV stained and mixed at a 1:1 ratio with pan-T cells from a healthy donor and incubated 1 h at room temperature.
  • the % of CD8-B cell conjugates and CD4-T cell conjugate was then assessed by flow cytometry after staining of CD4 and CD8 T cells after incubation with the MCAZ7.1 variant and the CD3 ⁇ CD20 bivalent engager.
  • a 3D-spheroid model was used to determine cytolytic activity of the MCAZ 7.1 variant as compared to the CD3 ⁇ CD20 bivalent engager.
  • GFP-expressing CD20+ B cell line (TMD8, 100 000 CD20/cell) were plated in low adherent plate to form 3D-spheroids for 72 h. Then, purified panT cells were added at a 15:1 E:T ratio and co-incubated with no engager, TENG0093, or CD3 ⁇ CD20 bivalent engager for 96 h.
  • GFP+ TMD8 cells were quantified using a Cellinsight CX7 HCS Platform imager.
  • the variant of MCAZ 7.1 provided potent CD20+ cell killing comparable to the CD3 ⁇ CD20 bivalent molecule ( FIG. 20 B ).
  • MCAZ7.1 and the CD3 ⁇ CD20 bivalent engager were incubated with OCI-Ly18 B cell line and PBMCs at an E:T ratio of 5:1 for 72 h.
  • Supernatants were harvested and analyzed by multiplex assay to measure the concentrations of released pro-inflammatory cytokines: ( FIG. 18 A ) IL-6, ( FIG. 18 B ) TNF- ⁇ , ( FIG. 18 C ) IL-10, ( FIG. 18 D ) IFN-g, ( FIG. 18 E ) IL-2, and ( FIG. 18 F ) IL-17A.
  • CD8-specific engagement of MCAZ7.1 provided similar Emax killing of CD20+ tumor cells as the CD3 ⁇ CD20 bivalent engager, but cytolysis was associated with significantly lower pro-inflammatory cytokine release than the CD3+ T cell engagement by the CD3 ⁇ CD20 bivalent engager.
  • the pharmacokinetics of MCAZ 7.1 was assessed after a single dose. Specifically, NSG mice humanized with panT cells were injected with 0.5 mg/kg of T cell engager and systemic concentrations of T cell engagers were measured after 1 h, 6 h, 24 h, 48 h, 72 h, and 168 h. The results demonstrate that the MCAZ 7.1 binding protein was stable in vivo ( FIG. 21 ).
  • mice were engrafted with panT cells two days prior to the study start.
  • 5e6 OCI-Ly18 CD20+ tumor cell lines were implanted s.c. at day 0 and animals were dosed i.p. with 1 mg/kg of MCAZ7.1 or the CD3 ⁇ CD20 bivalent engager at day 2, followed by weekly dosing at the same concentration as indicated by the grey arrows under the X axis.
  • MCAZ 7.1 and the CD3 ⁇ CD20 bivalent engager showed similar efficacy and complete tumor growth inhibition ( FIG. 22 ).
  • mice were irradiated (2.3 Gy) before engraftment with 10e6 PBMCs (i.p.) after 48 h, treated with Fc block (400 mg/mouse i.p.), and 24 h later treated with 2 mk/kg for OKT3 antibody (i.p.) or the indicated binding protein at 1 mg/kg (i.p.).
  • Blood was harvested at 6 h and 24 h post injection for assessment of cytokine concentration by multiplex assay.
  • B cell killing was assessed on PBMCs from NHL (DLBCL) donors.
  • the MCAZ 7.1 variant was spiked in the PBMCs at various concentrations and 48 h later, % B cells was assessed by flow cytometry for each patient.
  • Both CD8-specific T cell engagers, MCAZ 7.1 and the MCAZ 7.1 variant showed similar strong CD20+ B cell killing on PBMCs from non-Hodgkin lymphoma donors and confirmed strong CD8 T cell-biased activation ( FIGS. 24 A- 24 F ).
  • binding protein Based on the multitude of binding protein formats tested, a binding protein was identified with a novel conformation comprising the TCR binding domain and the T-cell co-stimulatory domain on separate arms located at the hinge region using an IgG Fc.
  • This binding protein advantageously had increased cytolytic activity and reduced incidence of cytokine release both in vitro and in vivo in the absence of tumor target cells (non-specific T cell activation) and during cytolytic activity in the presence of tumor target cells.
  • binding formats dislcosed herein provide reduced CD4 engagement compared to broad CD3 engagers including (i) limiting Treg activation and proliferation and limiting potential suppressive activity on CD8 cytolytic T cells, and (ii) reducing the engagement of other CD4 T cells subsets (Th1, Th2, Th9, TH17) all of which have been shown to be involved in that have been shown to be drivers of cytokine release syndrome events.
  • Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
  • the disclosure includes aspects in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
  • the disclosure includes aspects in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
  • the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
  • any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
  • elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any elements can be removed from the group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US18/854,215 2022-04-11 2023-04-06 T cell binding proteins Pending US20250346681A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/854,215 US20250346681A1 (en) 2022-04-11 2023-04-06 T cell binding proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329583P 2022-04-11 2022-04-11
PCT/EP2023/059278 WO2023198635A1 (en) 2022-04-11 2023-04-06 T cell binding proteins
US18/854,215 US20250346681A1 (en) 2022-04-11 2023-04-06 T cell binding proteins

Publications (1)

Publication Number Publication Date
US20250346681A1 true US20250346681A1 (en) 2025-11-13

Family

ID=86226585

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/854,215 Pending US20250346681A1 (en) 2022-04-11 2023-04-06 T cell binding proteins

Country Status (5)

Country Link
US (1) US20250346681A1 (https=)
EP (1) EP4508080A1 (https=)
JP (1) JP2025512953A (https=)
CN (1) CN118974091A (https=)
WO (1) WO2023198635A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3732201A4 (en) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Also Published As

Publication number Publication date
CN118974091A (zh) 2024-11-15
JP2025512953A (ja) 2025-04-22
EP4508080A1 (en) 2025-02-19
WO2023198635A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US12371505B2 (en) Anti-BCMA heavy chain-only antibodies
US20240124599A1 (en) Anti-bcma heavy chain-only antibodies
US20250346681A1 (en) T cell binding proteins
EP3823990B1 (en) Heavy chain antibodies binding to cd19
US11390681B2 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202206462A (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
US20240270840A1 (en) Antibodies against cd112r and uses thereof
US20250115678A1 (en) T cell binding compositions and methods
RU2781301C2 (ru) Анти-bcma антитела, содержащие только тяжёлую цепь
HK40093172A (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2026033437A1 (en) Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
HK40095391A (en) Anti-bcma heavy chain-only antibodies
BR112022021690B1 (pt) Anticorpos multiespecíficos, biespecíficos ou monoclonais, composição farmacêutica, usos dos mesmos, método de produção dos anticorpos multiespecíficos, biespecíficos ou monoclonais, kit, e moléculas biespecíficas semelhantes a anticorpo de três cadeias
BR122022022755B1 (pt) Anticorpos monoclonais biespecíficos, seus usos e seu método de produção, composição farmacêutica e kit
HK40022776A (en) Anti-bcma heavy chain-only antibodies

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION